Indian tennis star Ramkumar Ramanathan (Photo | PTI) 
Sports News

Ramkumar Ramanathan settles for runner-up finish at Challenger Eckental

Ramkumar Ramanathan, celebrating his 26th birthday, lost the summit clash 4-6 4-6 to Sebastian Korda, ranked 135.

From our online archive

ECKENTAL: Indian tennis player Ramkumar Ramanathan yet again settled for a runner-up finish on the Challenger circuit, losing the final of the Eckental event to American Sebastian Korda, here on Sunday.

The unseeded Indian, celebrating his 26th birthday, lost the summit clash 4-6 4-6 to his seventh seed rival, ranked 135, in one hour and 23 minutes.

It is now the fifth time that Ramkumar has not won a final on the Challenger circuit.

His previous runner-up finishes came at Tallahassee (April 2017), Winnetka (July 2017), Pune (November 2017) and Taipei (April 2018).

Nevertheless, it was Ramkumar's best performance of the 2020 season for which he earned Euro 7200 as prize money and 60 points that will push him to 185 from 206 in the ATP singles ranking charts.

His serve also looked decent in this tournament and he won many points by charging to the net.

Playing indoors also helped the Indian.

It was a tight contest, where killer instinct tilted it in favour of Korda, who has risen in ranks quite nicely since turning pro in 2018.

In the second set, serving at 4-4 and up 40-0, Ramkumar lost five straight points to drop his serve.

Korda's stunning service return winners showed he was hungry for this win.

Korda got to the match point with an ace, and clinched it when Ramkumar's forehand return crashed on to the net.

Why the additional declaration linked to Form 6 is facing a legal challenge

SP-Congress alliance faces fresh strain as Akhilesh skips INDIA bloc meet over UP seat-sharing talks

Rahul Gandhi tells CWC to continue 'resistance' against 'match-fixing' of polls through EVM, voters list

Assam Rifles jawan killed in militant attack in Arunachal; security forces intensify ops to arrest killers

SC slams medicine pricing, calls cancer drug’s 10-fold MRP markup ‘carnage’